OR WAIT 15 SECS
The program features an update on faricimab, plus diabetes, choroiditis, retinitis pigmentosa, and late-breaking reports.
In what is an annual ritual for many in the retinal community, Bascom Palmer Eye Institute carries on its 18th annual Angiogenesis, Exudation, and Degeneration 2021 meeting this February in a virtual setting across 2 days from Friday, Feb. 12, through Saturday, Feb. 13.
For program highlights for Friday, click here.
To attend the virtual meeting, registration must be received by Tuesday, February 9, at noon EST. Conference registration is $100 and the number of registrants is limited.
Here is an overview of presentations planned for Saturday’s program, which includes 4 sessions.
Following opening remarks by the program co-directors—Philip J. Rosenfeld, MD, PhD; Harry W. Flynn Jr., MD; and Thomas A. Albini, MD—the presentations will commence at 8 am Eastern.
Session IV: Emerging Therapies for Exudative AMD, will feature the following speakers:
Session V: Gene Therapy for Exudative AMD and Diabetic Retinopathy, begins at 9:15 am and will include:
Session VI: Dual Inhibition of Ang2 and VEGF for the Treatment of DME and Exudative AMD--An Update from the Faricimab Program is scheduled to begin at 10:00 am. The following presentations are scheduled:
Session VII: Diabetes, Choroiditis, Retinitis Pigmentosa and Late Breaking Reports, the final one of the conference, begins at 11:00 am and features: